Evidence map›Paper›PMID 32661618›Full record

ReviewInternational urology and nephrology2020

Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer.

Sidar Copur, Alan A Sag, Baris Afsar, Patrick Rossignol, Adrian Covic, Mehmet Kanbay

Abstract readReview
PubMed Publisher
In one paragraph

Review in International urology and nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Effects of acid on bone.Kidney international · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sidar CopurDepartment of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Alan A SagDivision of Vascular and Interventional Radiology, Department of Radiology, Duke University Medical Center, Durham, USA.
Baris AfsarDivision of Nephrology, Department of Internal Medicine, Suleyman Demirel University School of Medicine, Isparta, Turkey.
Patrick RossignolUniversité de Lorraine, INSERM CIC-P 1433, CHRU de Nancy, INSERM U1116, FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Adrian CovicDepartment of Nephrology, Grigore T. Popa' University of Medicine, Iasi, Romania.
Mehmet KanbayDepartment of Medicine, Division of Nephrology, Koc University School of Medicine, 34010, Istanbul, Turkey. mkanbay@ku.edu.tr.ORCID http://orcid.org/0000-0002-1297-0675

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease is prevalent, affecting more than one in ten adults. In this population, metabolic acidosis is considered a key underlying pathophysiological feature, tying together bone mineral disorders, sarcopenia, insulin resistance, vascular calcification, pro-inflammatory and pro-thrombotic states. This review aims to address the paucity of literature on alkalinizing agents, a promising treatment option that has known adverse effects.

Indexed as

AcidosisAntacidsHumansRenal Insufficiency, ChronicAntacidsAlkaline treatmentBicarbonateChronic kidney diseaseEnd-stage renal diseaseMetabolic acidosis

Identifiers

PMID32661618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.